PALO ALTO, Calif.--(BUSINESS WIRE)--ShangBay Capital, a Silicon Valley based venture capital firm focused on Medtech and Biotech start-up and emerging growth companies, announces the appointments of Mr. Erik Engelson as Venture Partner, and Dr. Yajun Xu as Senior Advisor. "We are excited to have Erik and Yajun leverage their experience and networks with ShangBay Capital," commented ShangBay Capital Founding Partner William Dai.
Mr. Engelson brings three decades of medical device development and commercialization experience, and currently serves as board member and strategic advisor to Arrinex, Inc and ARANZ Medical, Ltd. Mr. Engelson previously served as CEO of Medina Medical, which was sold to Medtronic PLC. Previous associations include Partner at The Foundry, a medical device incubator, CEO of two Foundry companies, CFO of Fluidigm Corporation, and Venture Partner at both Versant Ventures and Institutional Venture Partners. Earlier, Mr. Engelson spent 13 years in various operating roles at Target Therapeutics where he led the early start-up into the then nascent field of Interventional Neuroradiology, developed its first products and helped take the company public. He is the inventor of 50+ medical device patents. Mr. Engelson holds B.A. and M.S. degrees in Microbiology and Bioengineering from UC San Diego, and an Executive MBA from the Stanford Graduate School of Business.
Yajun Xu has more than 20 years’ experience in drug discovery and development. Yajun is currently President of Shangpharma Investment Group. Yajun is also co-founder of Epimab Biotherapeutics (a biotech company based in China), board member of Abcuro therapeutics (a biotech company), advisor to ZAI Lab Limited (a biopharma, Shanghai based) and advisor for Hotspot Therapeutics (a biotech company).
Dr. Yajun was previously senior vice president of corporate development of Shangpharma. Yajun was the founder, vice president of biology and pre-clinical service platform for Shanghai ChemPartner (a CRO company based in China) from 2007 to 2014. Prior to ChemPartner, Yajun was Director of Research at Millennium Pharmaceuticals Inc., where she worked for 6 years and managed the small molecule kinase inhibitor portfolios for the inflammation/immunology indication. Previously, Yajun was a senior scientist at BASF Bioresearch Corp. where she supported drug discovery programs in both inflammation and oncology. Yajun received her Ph.D. in Biochemistry at Brandeis University, and postdoctoral training at Harvard’s School of Public Health. She received MS and BS degrees in Chemistry from Beijing University of Chemical Technology in China.
ShangBay Capital, based in Palo Alto, California, is a venture capital firm focused on Medtech and Biotech Healthcare.